– USA, MA – CANbridge Pharmaceuticals Inc. (HKEX: 1228), a global biopharmaceutical company today announced the appointment of Edward Hu to its Board as a non-executive director effective immediately, replacing Xiao Le, who resigned from the board.
“We are delighted that Ed is joining the CANbridge Board, where we know his depth of industry experience in finance, operations and capital markets will be a tremendous asset as we advance as a global rare disease biopharmaceutical company with three approved and multiple clinical-stage products,” said Founder, Chairman and CEO Dr. James Xue.
He will also join the Remuneration Committee
About Edward Hu
Edward Hu has deep and varied C-level biopharmaceutical experience, having served as both Co-CEO and CEO at WuXi AppTec before his current position as Vice Chairman, Global CIO, Executive Director, Strategy Committee Member. Before then, Mr. Hu was CFO and COO at WuXi PharmaTech. Prior to his roles at WuXi, Mr. Hu held multiple senior management roles, culminating in that of SVP and COO at Tanox Inc., a NASDAQ-traded public company, which was acquired by Genentech. Prior to that, Mr. Hu served as business planning manager of Biogen Inc, and before then, as senior financial analyst at Merck. Mr. Hu is currently a non-executive director of CStone Pharmaceuticals. Previously, he also served as non-executive director of WuXi Biologics, as well as a director of Viela Bio Inc, which was acquired by Horizon Therapeutics in March 2021.
“CANbridge has undergone significant recent growth as it continues to position itself to become a global rare disease biopharmaceutical leader,” said Edward Hu. “I look forward to being an integral part of the Board helping to shape this strategy.”
Mr. Hu has a bachelor’s degree in physics from Hangzhou University in Zhejiang province, China. He also has a master’s degree in chemistry and a master’s degree in business administration, both from Carnegie Mellon University, in Pittsburgh, Pennsylvania.
About CANbridge Pharmaceuticals Inc.
CANbridge Pharmaceuticals Inc. is a China and US-based global biopharmaceutical company committed to the research, development and commercialization of transformative therapies for rare disease and rare oncology. CANbridge has a differentiated drug portfolio, with three approved drugs and a pipeline of 10 assets, targeting prevalent rare disease and rare oncology indications that have unmet needs and significant market potential. These include Hunter syndrome and other lysosomal storage disorders, complement-mediated disorders, hemophilia A, metabolic disorders, rare cholestatic liver diseases and neuromuscular diseases, as well as glioblastoma multiforme. CANbridge is also building next-generation gene therapy development capability through a combination of collaboration with world-leading researchers and biotech companies and internal capacity. CANbridge global partners include: Apogenix, GC Pharma, Mirum, Wuxi Biologics, Privus, the UMass Chan Medical School, the University of Washington School of Medicine, Scriptr Global and LogicBio.
For more information : https://www.canbridgepharma.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.